Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov 27;2013(11):CD001990.
doi: 10.1002/14651858.CD001990.pub3.

Chemotherapy versus best supportive care for extensive small cell lung cancer

Marta Pelayo Alvarez  1 , Virginie Westeel, Marcela Cortés-Jofré, Xavier Bonfill Cosp
Affiliations
Review

Chemotherapy versus best supportive care for extensive small cell lung cancer

Marta Pelayo Alvarez et al. Cochrane Database Syst Rev. .

Abstract

Background: Combination chemotherapy has been the mainstay of treatment for extensive stage small celI lung cancer (SCLC) over the last 30 years, even though it only gives a short prolongation in median survival time. The main goal for these patients should be palliation with the aim of improving their quality of life.

Objectives: To determine the effectiveness of first-line chemotherapy versus placebo or best supportive care (BSC) in prolonging survival in patients with extensive SCLC at diagnosis and the effectiveness of second-line chemotherapy at relapse or progression after first-line chemotherapy compared with BSC or placebo in prolonging survival in patients with extensive SCLC; as well as to evaluate the adverse events of treatment and the quality of life of patients.

Search methods: This is the second update of the review. MEDLINE (1966 to October 2013), EMBASE (1974 to October 2013), and the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 3) were searched. Experts in the field were contacted.

Selection criteria: Phase III randomised controlled trials in which any chemotherapy treatment was compared with placebo or BSC in patients with extensive SCLC, as first-line or second-line therapy at relapse.

Data collection and analysis: Two authors independently extracted data and assessed study quality. We resolved disagreements by discussion. Additional information was obtained from one study author.

Main results: Two studies of unclear risk of bias were included for first-line chemotherapy. A total of 88 men under 70 years with good performance status were randomised to receive either supportive care, placebo infusion or ifosfamide. Ifosfamide gave an extra mean survival of 78.5 days compared with supportive care or placebo infusion. Partial tumour response was greater with the active treatment. Toxicity was only seen in the chemotherapy group and quality of life was only assessed at the beginning of treatment. The quality of the evidence for overall survival and adverse effects was very low.Three studies of moderate risk of bias were included for second-line chemotherapy at relapse (one identified in the last search). A total of 932 men and women under 75 years and any performance status were randomised to receive either methotrexate-doxorubicin, topotecan, or picoplatin versus symptomatic treatment or BSC. The methotrexate-doxorubicin treatment gave a median survival of 63 days longer than in the symptomatic-treatment group for patients allocated to receive four cycles of first-line chemotherapy, and 21 days longer for patients allocated to receive eight cycles of first-line chemotherapy.Treatment with topotecan gave a median survival of 84 days longer than in the BSC group (log-rank P = 0.01). The adjusted hazard ratio (HR) for overall survival was 0.61 (95% CI 0.43 to 0.87). Treatment with picoplatin gave a median survival time of six days longer than BSC (HR 0.817, 95% CI 0.65 to 1.03, P = 0.0895). A meta-analysis of topotecan and picoplatin gave a HR of 0.73 (95% CI 0.55 to 0.96, P = 0.03; low-quality evidence).Partial or complete response in the methotrexate-doxorubicin group was 22.3%. Five patients (7%, 95% CI 2.33 to 15.67) showed a partial response with topotecan. No data were provided about tumour response in the picoplatin study. Toxicity was worst in the chemotherapy group (moderate-quality evidence). Quality of life was better in the topotecan group and was not measured in the methotrexate-doxorubicin and picoplatin studies (low-quality evidence).

Authors' conclusions: Two small RCTs from the 1970s suggest that first-line chemotherapeutic treatment (based on ifosfamide) may provide a small survival benefit (less than three months) in comparison with supportive care or placebo infusion in patients with advanced SCLC. However platinum-based combination chemotherapy regimens have been shown to increase complete response rates when compared to non-platinum chemotherapy regimens with no significant difference in survival, and so these are currently the standard first-line treatment for patients with SCLC.Second-line chemotherapy at relapse or progression may prolong survival for some weeks in relation to BSC. Nevertheless, the impact of first-line chemotherapy on quality of life, older patients, women and patients with poor prognosis is unknown and the benefits of second-line chemotherapy are also unclear for older people. Globally, the evidence on which these conclusions are based is very scarce and of uncertain or low quality, which calls for well-designed, controlled trials to further evaluate the trade-offs between benefits and risks of different chemotherapeutic schedules in patients with advanced SCLC.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Second‐line chemotherapy at relapse versus BSC, outcome: 1.1 Overall survival.
1.1
1.1. Analysis
Comparison 1 Second‐line chemotherapy at relapse versus best supportive care (BSC), Outcome 1 Overall survival.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Ciuleanu 2010 {published data only}
    1. Ciuleanu T, Samarzjia M, Demidchik Y, Beliakouski V, Rancic M, Bentsion DL, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO) 2010;28(15 Suppl):7002.
Kokron 1977b {published data only}
    1. Kokron O, Titscher R, Micksche M, Cerni C, Wrba H. Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin 1977;15:103‐8. - PubMed
Kokron 1982 {published data only}
    1. Kokron O, Mickshe M, Titscher R, Wrba H. Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie 1982;56:56‐9. - PubMed
O'Brien 2006 {published data only}
    1. O'Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology 2006;24:5441‐7. - PubMed
O'Brien 2007a {published data only}
    1. O'Brian ME, Duh MS, Chen L, Antras L, Neary M, Gralla RJ. An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1‐224. Journal of Thoracic Oncology 2007;2(8):S827.
Spiro 1989 {published data only}
    1. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 1989;59:578‐83. - PMC - PubMed

References to studies excluded from this review

AlIan 1984 {published data only}
    1. Allan SG, Gregor A, Cornbleet MA, Leonard RC, Smyth JF, Grant IW, et al. Phase II trial of vindesine and VP16‐213 in the palliation of poor‐prognosis patients and elderly patients with small cell lung cancer. Cancer Chemotherapy and Pharmacology 1984;13:106‐8. - PubMed
Anderson 1993 {published data only}
    1. Anderson FI, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L. A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. British Journal of Cancer 1993;67:1385‐90. - PMC - PubMed
Ardizzoni 2002 {published data only}
    1. Ardizzoni A, Tjan‐Heijnen VCG, Postmus PE, Buchholz E, Biesma B, Karnicka Mlodkowska FI, et al. Standard versus intensified chemotherapy with granulocyte colony‐stimulating factor support in small‐cell lung cancer: A prospective European Organization for Research and Treatment of Cancer‐Lung Cancer Group phase III trial‐08923. Journal of Clinical Oncology 2002;20:3947‐55. - PubMed
Beith 1996 {published data only}
    1. Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA. Long‐term follow‐up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. European Journal of Cancer 1996;32A:438‐43. - PubMed
Bleehen 1989 {published data only}
    1. Bleehen NM, Fayers PM, Girling DJ, Stephens RJ. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. British Journal of Cancer 1989;59:584‐90. - PMC - PubMed
Bleehen 1993 {published data only}
    1. Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party. British Journal of Cancer 1993;68:1157‐66. - PMC - PubMed
Bleehen 1996 {published data only}
    1. Bleehen NM, Girling D, Hopwood P, Lallemand G, Machin D, Stephens RI, et al. Randomised trial of four‐drug vs less intensive two‐drug chemotherapy in the palliative treatment of patients with small‐cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406‐13. - PMC - PubMed
Candido 2002 {published data only}
    1. Candido P, Cavallaro G, Piatti G, Bucchioni E. Results of a combined phase II study on small celI lung cancer. Giornale Italiano Delle Malattie del Torace 2002;56:105‐12.
Chen 2007 {published data only}
    1. Chen L, Antras L, Duh MS, Pickard S, Cella D, Neary M, et al. Is treatment with oral topotecan plus best supportive care associated with better health status compared to best supportive care alone in small cell lung cancer?: D1‐06. Journal of Thoracic Oncology 2007;2(8):S391‐2.
Ciuleanu 2002 {published data only}
    1. Ciuleanu TE, Curca R, Iancu D, Todor N, Cebotaru C, Fadulescu I, et al. First‐Iine chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study. Journal of the Balkan Union of Oncology 2002;7:43‐6. - PubMed
CuIlen 1986 {published data only}
    1. Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, et al. Maintenance chemotherapy for anaplastic small celI carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemotherapy and Pharmacology 1986;17:157‐60. - PubMed
EarI 1991 {published data only}
    1. Earl HM, Rudd RM, Spiro SG, Ash CM, James LE, Law CS, et al. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 1991;64:566‐72. - PMC - PubMed
Eridani 1978 {published data only}
    1. Eridani S, Burdick L, Maggio L, Cunietti E, Periti M, Arosio A, et al. Combined chemotherapy for unresectable carcinoma of the lung: a randomised trial. International Journal of Clinical Pharmacology & Biopharmacy 1978;16:182‐5. - PubMed
Ettinger 1990 {published data only}
    1. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomised comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive‐stage small‐cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 1990;8:230‐40. - PubMed
Garassino 2011 {published data only}
    1. Garassino MC, Torri V, Michetti G, Lo Dico M, Verde N, Sglione S, et al. Outcomes of small‐cell lung cancer patients treated with second‐line chemotherapy: A multi‐institutional retrospective analysis. Lung Cancer 2011;72:378‐83. - PubMed
Giaccone 1993 {published data only}
    1. Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, et al. Maintenance chemotherapy in small cell lung cancer: long‐term results of a randomised trial. Journal of Clinical Oncology 1993;11:1230‐40. - PubMed
Green 1969 {published data only}
    1. Green R, Humphrey E, Close H, Patno M. Alkylating Agents in Bronchogenic Carcinoma. American Journal of Medicine 1969;46:516‐25. - PubMed
GrideIIi 2002 {published data only}
    1. Gridelli C, Rossi A, Barletta E, Panza N, Brancaccio L, Cioffi R, et al. Carboplatin plus vinorelbine plus G‐CSF in elderly patients with extensive‐stage small‐cell lung cancer: a poorly tolerated regimen. Results of a multi‐centre phase II study. Lung Cancer 2002;36:327‐32. - PubMed
Hainsworth 2002 {published data only}
    1. Hainsworth ID, Morrissey LH, Scullin DC Jr, Houston GA, Prasthofer EF, Gray JR, et al. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small celI lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 2002;94:2426‐33. - PubMed
Hanna 2002 {published data only}
    1. Hanna NH, Sandler AB, Loehrer PJ, Ansari R, Jung SH, lane K, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small‐cell lung cancer: a Hoosier Oncology Group randomised study. Annals of Oncology 2002;13:95‐102. - PubMed
James 1996 {published data only}
    1. James LE, Gower NH, Rudd RM, Spiro SG, Harper PG, Trask CW, et al. A randomised trial of low‐dose/high‐frequency chemotherapy as palliative treatment of poor‐prognosis small‐ceIl lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 1996;73:1563‐8. - PMC - PubMed
Joss 1995 {published data only}
    1. Joss RA, Alberto P, Hurny C, Bacchi M, Leyvraz S, Thurlimann B, et al. Quality versus quantity of life in the treatment of patients with advanced small‐cell lung cancer? A randomised phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology 1995;6:41‐8. - PubMed
Kokron 1974a {published data only}
    1. Kokron O. [Die Behandlung des kleinzelligen metastasierenden Bronchuskarzinoms mit Ifosfamid. Ergebnisse einer prospectiven randomisierten Studie]. Österreichische Zeitschrift für Onkologie 1974;5‐6:123‐7. - PubMed
Kokron 1974b {published data only}
    1. Kokron O. Treatment of oat cell metastazing bronchial carcinoma with isofosfamide. Results of a prospective randomised study [Die Behandlung des kleinzelligen Bronchuskarzinoms]. Osterreichische Kneipp Magazin 1974;5‐6:123‐7. - PubMed
Kokron 1977a {published data only}
    1. Kokron O. [Klinische Erfahrungen mit Holoxan beim kleinzelligen Bronchuskarzinom]. Österreichische Zeitschrift für Onkologie 1977;4:103‐6. - PubMed
Korfel 2002 {published data only}
    1. Korfel A, Oehm C, Pawel J, Keppler U, Deppermann M, Kaubitsch S, et al. Response to topotecan of symptomatic brain metastases of small‐cell lung cancer also after whole brain irradiation. A multi‐centre phase II study. European Journal of Cancer 2002;38:1724‐9. - PubMed
Lebeau 1992 {published data only}
    1. Lebeau B, Chastang Cl, Allard P, Migueres J, Boita F, Fichet D, et al. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomised clinical trial. European Respiratory Journal 1992;5:286‐90. - PubMed
Lyss 2002 {published data only}
    1. Lyss AP, Herndon lI JE, Lynch Jr TJ, Turrisi AT, Watson DM, Grethlein SJ, et al. Novel doublets in extensive‐stage small‐cell lung cancer: A randomised phase II study of topotecan plus cisplatin of paclitaxel (CALGB 9430). Clinical Lung Cancer 2002;3:205‐10. - PubMed
Mattson 1992 {published data only}
    1. Mattson K, Niiranen A, Pyrhönen S, Holsti LR, Holsti P, Kumpulainen E, et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. European Journal of Cancer 1992;28A:1387‐91. - PubMed
Mattson 1997 {published data only}
    1. Mattson K, Niiranen A, Ruotsalainen T, Maasilta P, Halme M, Pyrhönen, et al. Interferon maintenance therapy for small cell lung cancer: improvement in long‐term survival. Journal of Interferon and Cytokine Research 1997;17:103‐5. - PubMed
Maurer 1980 {published data only}
    1. Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O, et al. A randomised combined modality trial in small cell carcinoma of the lung. Cancer 1980;45:30‐9. - PubMed
Mok 2002 {published data only}
    1. Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, et al. A Phase I‐II study of sequential administration of topotecan and oral etoposide (toposiomerase 1 and II inhibitors) in the treatment of patients with small celI lung carcinoma. Cancer 2002;95:1511‐9. - PubMed
Naka 2002 {published data only}
    1. Naka N, Kawahara M, Okishio K, Hosoe S, Ogawara M, Atagi S, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small‐cell lung cancer. Lung Cancer 2002;37:319‐23. - PubMed
Noda 2002 {published data only}
    1. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small‐cell lung cancer. New England Journal of Medicine 2002;346:85‐91. - PubMed
Reck 1998 {published data only}
    1. Reck M, Haering B, Koschel G, Kaukel E, Pawel J, Gatzemeier U. Chemotherapy of advanced SCLC and NSCLC with Bendamustine ‐ A phase II‐study. Pneumologie 1998;52:570‐3. - PubMed
Rosenthal 1991 {published data only}
    1. Rosenthal M, Kefford R, Raghavan D, Stuart‐Harris R. Epirubicin: a phase II study in recurrent small‐cell lung cancer. Cancer Chemotherapy and Pharmacology 1991;28:220‐2. - PubMed
Schiller 2001 {published data only}
    1. Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH. Topotecan versus observation alter cisplatin plus etoposide in extensive‐stage small‐cell lung cancer: E7593 ‐ A phase III trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001;19:2114‐22. - PubMed
Sculier 1996 {published data only}
    1. Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small‐cell lung cancer. Journal of Clinical Oncology 1996;14:2337‐44. - PubMed
Smit 1989 {published data only}
    1. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 1989;44:631‐3. - PMC - PubMed
Souhami 1997 {published data only}
    1. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al. Five‐day oral etoposide treatment for advanced small‐cell lung cancer: randomised comparison with intravenous chemotherapy. Journal of the National Cancer Institute 1997;89:577‐80. - PubMed
Sundstrom 2002 {published data only}
    1. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small‐cell lung cancer: results from a randomised phase III trial with 5 years follow‐up. Journal of Clinical Oncology 2002;20:4665‐72. - PubMed
Tada 2002 {published data only}
    1. Tada A, Ueoka H, Kiura K, Tabata M, Takemoto M, Yamane H, et al. Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer. [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 2002;29:751‐6. - PubMed
Thatcher 1996 {published data only}
    1. Thatcher N, Clark PI, Girling DJ, Hopwood P, Twiddy S, Stephens RJ, et al. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small‐cell lung cancer: A stopped multi‐centre randomised trial. Lancet 1996;348:563‐6. - PubMed
Thomas 2002 {published data only}
    1. Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD. A phase II study of CI‐980 in previously untreated extensive small celI lung cancer: an Ohio State University phase II research consortium study. Cancer Investigation 2002;20:192‐8. - PubMed
Tjan‐Heíjnen 2001 {published data only}
    1. Tjan‐Heijnen VCG, Postmus PE, Ardizzoni A, Manegold Ch, Burghouts J, Van‐Meerbeeck J, et al. Reduction of chemotherapy‐induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small‐cell lung cancer patients: An EORTC double‐blind placebo‐controlled phase III study. Annals of Oncology 2001;12:1359‐68. - PubMed
Vanseenkiste 2001 {published data only}
    1. Vansteenkiste J, Gatzemeier U, Manegold C, Hanauske A, Weynants P, Bosquée L, et al. Gemcitabine plus etoposide in chemo‐naive extensive disease small‐ceIl lung cancer: A multi‐centre phase II study. Annals of Oncology 2001;12:835‐40. - PubMed
von Pawel 1990 {published data only}
    1. Pawel J, Wilke H, Vahee D, Dimbeck H, Schmohl HJ. Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease), [Article in German]. Pneumologie 1990;44:582‐3. - PubMed
Zhang 2002 {published data only}
    1. Zhang Z, Hu Z, Lu X, Zeng L. Evaluation of topotecan combined with cisplatin in the treatment of small cell Iung cancer. Chinese Journal of Lung Cancer 2002;5:354‐6. - PubMed

Additional references

Amarasena 2009
    1. Amarasena IU, Walters JAE, Wood‐Baker R, Fong K. Platinum versus non‐platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006849.pub2] - DOI - PubMed
Bell 2013
    1. Bell M, Kenward MG, Fairclough DL, Horton NJ. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ 2013;346:e8668. - PMC - PubMed
Bernhard 1996
    1. Bernhard J, Hürny C, Bacchi M, Joss RA, Cavalli F, Senn HJ, et al. Initial prognostic factors in small‐celI lung cancer patients predicting quality of life during chemotherapy. British Journal of Cancer 1996;74:1660‐7. - PMC - PubMed
Carney 2002
    1. Carney D. Lung cancer ‐ Time to move on from chemotherapy. New England Journal of Medicine 2002;346:126‐7. - PubMed
Cheng 2007
    1. Cheng S, Evans WK, Stys‐Norman D, Shepherd FA, the Lung Cancer Disease Site Group of Cancer Care Ontario' Program in Evidence‐based Care. Chemotherapy for relapse small cell lung cancer: a systematic review and practice guideline. Journal of Thoracic Oncology 2007;2:348‐54. - PubMed
Chutte 1999
    1. Chute J, Chen T, Feigal E, Simon R, Johnson B. Twenty years of phase III trials for patients with extensive‐stage small celI lung cancer: perceptible progress. Journal of Clinical Oncology 1999;17:1794‐801. - PubMed
Ciani 2013
    1. Ciani O, Buyse M, Garside R, Pavey T, Stein K, Sterne J, et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta‐epidemiological study. BMJ 2013;346:457‐69. - PMC - PubMed
Cortés‐Jofré 2012
    1. Cortés Jofré M, Rueda JR, Corsini‐Muñoz G, Fonseca‐Cortés C, Carballoso M, Bonfill Cosp X. Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD002141.pub2] - DOI - PubMed
Day 2000
    1. Day SJ, Altman DG. Blinding in clinical trials and other studies. BMJ 2000;321:504. - PMC - PubMed
De Vita 2000
    1. Vita V, Hellan S, Rosemberg S. Cancer: Principles & Practice of Oncology. Sixth. Philadelphia: Lippincott, 2000.
De Wet 1994
    1. Wet M, Falkson G, Rapoport BL. Small cell Iung cancer: analysis of factors influencing the response to treatment and survival. Oncology 1994;51:523‐34. - PubMed
Dumville 2006
    1. Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. BMJ 2006;332:969‐71. - PMC - PubMed
Govindan 2006
    1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small‐cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology 2006;24:4539‐44. - PubMed
Gralla 2004
    1. Gralla RJ. Quality of life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The Oncologist 2004;9 Suppl 6:14‐24. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011].. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hollen 1994a
    1. Hollen Pi, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994;73:2087‐98. - PubMed
Hollen 1994b
    1. Hollen Pi, Gralla RJ, Kris MG, Cox C. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Supportive Care in Cancer 1994;2:213‐22. - PubMed
Ihde 1992
    1. Ihde DC. Chemotherapy of lung cancer. New England Journal of Medicine 1992;327:1434‐41. - PubMed
Kim 2008
    1. Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, et al. Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy. Cancer 2008;113:2518‐23. - PubMed
Kleinbaum 1996
    1. Kleinbaum DG. Survival analysis: A self‐learning text. New York: Springer‐Verlag, 1996.
Lacombe 1997
    1. Lacombe D. Ethical Issues in cancer clinical trials: a European Perspective. European Journal of Cancer 1997;33:184‐5. - PubMed
Lassen 1998
    1. Lassen, Hirsch FR, Osterlind K, Bergman B, Dombernoswky P. Outcome of combination chemotherapy in extensive stage small‐celI lung cancer: any treatment related progress?. Lung Cancer 1998;20:151‐60. - PubMed
Loveman 2010
    1. Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A. The clinical effectiveness and cost‐effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technological Assessment 2010;14(19):1‐6. - PubMed
Lundh 2012
    1. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. - PubMed
Manser 2010
    1. Manser R, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D. Screening for lung cancer. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001991.pub2] - DOI
Moore 1998
    1. Moore RA, Gevaghan D, Traver MR, Collins S, McQuay HJ. Size is everything. The impact of event rate variation on clinical trials and meta‐analysis. Pain 1998;78:208‐16.
Owonikoko 2007
    1. Owonikoko TK, Ragin CC, Belani ChP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology 2007;25:5570‐7. - PubMed
Oze 2009
    1. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al. Twenty‐seven years of phase III trials for patients with extensive disease small‐cell lung cancer: disappointing results. PLOS ONE 2009;4:e7835. - PMC - PubMed
Rawson 1990
    1. Rawson NS, Peto J. An overview of prognostic factors in small cell Lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. British Journal of Cancer 1990;61:597‐604. - PMC - PubMed
Riaz 2012
    1. Riaz PS, Lüchtenborg M, Coupland HV, Spicer J, Peake DM, Moller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 2012;75:280‐4. - PubMed
Riemsma 2010
    1. Riemsma R, Simons JP, Bashir Z, Gooch CL, kleijnen J. Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer 2010;10:436‐48. - PMC - PubMed
Rothwell 2005
    1. Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005;365:176‐86. - PubMed
Seidenfeld 2006
    1. Seidenfeld J, Samson DJ, Bonnell CJ, Ziegler KM, Aronson N. Management of small cell lung cancer. Evidence Report/Technology Assessment No 143. AHRQ Publication No. 06‐E016. Rockville, MD: Agency for Health Research and Quality July 2006. - PMC - PubMed
Souhami 1988
    1. Souhami RL, Morittu L, Ash CM, EarI H, Geddes D, Harper PG, et al. Identification of patients at high risk of chemotherapy induced toxicity in SCLC. Antibiotics and Chemotherapy 1988;41:220‐5. - PubMed
Souhami 1990
    1. Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer SubCommitee of the United Kingdom Coordinating Commitee for Cancer Research. British Journal of Cancer 1990;61:584‐9. - PMC - PubMed
Sugiyama 2008
    1. Sugiyama T, Hirose T, Hosaka T, Kusumoto S, Nakashima M, Yamaoka T, et al. Effectiveness of intensive follow‐up after response in patients with small cell lung cancer. Lung Cancer 2008;59:255‐61. - PubMed
Sundstr¢m 2005
    1. Sundstr¢m S, Bremnes RM, Kaasa S, Aaseb¢ U, Aamdal S. Second‐line chemotherapy in recurrent small lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP‐regimen) or cyclophosphamide, epirubicin, and vincristin (CEV‐regimen). Lung Cancer 2005;48:251‐61. - PubMed
Vrdoljak 2001
    1. Vrdoljak E, Mise K, Sapunar A, Rozga A, Marusic M. Staging in untreated patients with small cell Iung cancer. Neoplasma 2001;48:154‐6. - PubMed
Weatley‐Price 2010
    1. Wheatley‐Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, et al. The strength of female sex as prognostic factor in small‐cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. Annals of Oncology 2010;21:232‐7. - PubMed
Weeks 2012
    1. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients' expectations about effects of chemotherapy for advanced cancer. New England Journal of Medicine 2012;367:1616‐25. - PMC - PubMed
Wolf 2004
    1. Wolf M, Tebbe S, Fink T. First‐line chemotherapy in metastatic small‐cell lung cancer (SCLC). Lung Cancer 2004;Suppl 2:S223‐34. - PubMed
Zelen 1973
    1. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemotherapy Reports. Part 3 1973;4:31‐42. - PubMed

References to other published versions of this review

Agra 2003
    1. Agra Varela Y, Pelayo Alvarez M, Sacristan M, Sacristan Rodea A, Serra C, Bonfill Cosp X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD001990] - DOI - PubMed
Pelayo 2009
    1. Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, Agra Varela Y. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD001990.pub2] - DOI - PubMed

MeSH terms